Re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032: Interpreting the Effect of Ipilimumab Following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer

Eur Urol. 2021 Jan;79(1):e10-e11. doi: 10.1016/j.eururo.2020.09.049. Epub 2020 Oct 24.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Abiraterone Acetate
  • Humans
  • Ipilimumab
  • Male
  • Prostatic Neoplasms*
  • Prostatic Neoplasms, Castration-Resistant* / drug therapy
  • Survivors

Substances

  • Ipilimumab
  • Abiraterone Acetate